Zhengyan Cai

Zhengyan Cai


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YDYuanzhen Dong
Yuanzhen Dong
JZJinhua Zhang
Jinhua Zhang
HXHongjiang Xu
Hongjiang Xu
HSHengqiao Shen
Hengqiao Shen
QLQin Lu
Qin Lu
ZCZhengyan Cai
Zhengyan Cai

5 June 2025 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CWChengcheng Wang
Chengcheng Wang
JZJinhua Zhang
Jinhua Zhang
YDYuanzhen Dong
Yuanzhen Dong
JXJun Xu
Jun Xu
JLJianguang Lu
Jianguang Lu
JFJun Feng
Jun Feng

Verified
Journal Article
Open access
PDF file
WWWenqiang Wu
Wenqiang Wu
LCLuo Cheng-Miao
Luo Cheng-Miao
CZChunhui Zhu
Chunhui Zhu
ZCZhengyan Cai
Zhengyan Cai
JLJianyong Liu
Jianyong Liu
Photodynamic Therapy (PDT) is recognized for its exceptional effectiveness as a promising cancer treatment method. However, it is noted that overexposure to the dosage and sunlight in traditional PDT can result in damage to healthy tissues, due to the low tumor selectivity of currently available photosensitizers (PSs). To address this challenge, we introduce herein a new strategy where the small molecule-targeted agent, erlotinib, is integrated into a boron dipyrromethene (BODIPY)-based PS to form conjugate 6 to enhance the precision of PDT. This conjugate demonstrates optical absorption, fluorescence emission, and singlet oxygen generation efficiency comparable to the reference compound 7, which lacks erlotinib. In vitro studies reveal that, after internalization, conjugate 6 predominantly accumulates in the lysosomes of HepG2 cells, exhibiting significant photocytotoxicity with an IC50 value of 3.01 µM. A distinct preference for HepG2 cells over HELF cells is observed with conjugate 6 but not with compound 7. In vivo experiments further confirm that conjugate 6 has a specific affinity for tumor tissues, and the combination treatment of conjugate 6 with laser illumination can effectively eradicate H22 tumors in mice with outstanding biosafety. This study presents a novel and potential PS for achieving precise PDT against cancer.

5 May 2026 in ACS Omega
Verified
Journal Article
Open access
YLYubin Liu
Yubin Liu
KLKuaile Lin
Kuaile Lin
XYXi Yan
Xi Yan
GLGang Li
Gang Li
HCHongming Cai
Hongming Cai
RZRonghua Zhang
Ronghua Zhang
The incorporation of alkene bonds into aromatic heterocyclic skeletons offers an efficient and straightforward strategy for molecular splicing and extension of conjugated systems, while also paving the way for the development of novel functional molecules. However, conventional approaches often depend on aldehyde or ketone precursors, involve multistep sequences, or require harsh reaction conditions, which considerably restrict their applicability. Herein, we present a single-step photoinduced alkene coupling reaction using quinoxalinones and indoleones that proceeds in high yield within a recyclable ionic liquid medium. This process exploits the inherent photosensitivity of the substrates to achieve autocatalysis, eliminating the need for an external photocatalyst, and proceeds under mild conditions with only a stoichiometrically minimal amount of oxidant. The method demonstrates strict stereoselectivity, broad substrate scope, and good functional group tolerance. Mechanistic investigations indicate a radical-based mechanism, wherein photoexcitation generates radical species that are regenerated via hydrogen atom transfer between the photoactive substrate and the radical intermediate. Given the significance of aromatic heterocyclic conjugated systems in pharmaceuticals and energy-related materials, this photocatalytic alkene coupling strategy holds considerable potential for practical applications.